Phosphatidylserine-specific phospholipase A1: A friend or the devil in disguise.

Autoimmunity Cancer Lysophosphatidylserine Lysophosphatidylserine receptors PLA1A Phosphatidylserine

Journal

Progress in lipid research
ISSN: 1873-2194
Titre abrégé: Prog Lipid Res
Pays: England
ID NLM: 7900832

Informations de publication

Date de publication:
07 2021
Historique:
received: 19 03 2021
revised: 30 04 2021
accepted: 18 06 2021
pubmed: 25 6 2021
medline: 18 1 2022
entrez: 24 6 2021
Statut: ppublish

Résumé

Various human tissues and cells express phospholipase A1 member A (PLA1A), including the liver, lung, prostate gland, and immune cells. The enzyme belongs to the pancreatic lipase family. PLA1A specifically hydrolyzes sn-1 fatty acid of phosphatidylserine (PS) or 1-acyl-lysophosphatidylserine (1-acyl-lysoPS). PS externalized by activated cells or apoptotic cells or extracellular vesicles is a potential source of substrate for the production of unsaturated lysoPS species by PLA1A. Maturation and functions of many immune cells, such as T cells, dendritic cells, macrophages, and mast cells, can be regulated by PLA1A and lysoPS. Several lysoPS receptors, including GPR34, GPR174 and P2Y10, have been identified. High serum levels and high PLA1A expression are associated with autoimmune disorders such as Graves' disease and systemic lupus erythematosus. Increased expression of PLA1A is associated with metastatic melanomas. PLA1A may contribute to cardiometabolic disorders through mediating cholesterol transportation and producing lysoPS. Furthermore, PLA1A is necessary for hepatitis C virus assembly and can play a role in the antivirus innate immune response. This review summarizes recent findings on PLA1A expression, lysoPS and lysoPS receptors in autoimmune disorders, cancers, cardiometabolic disorders, antivirus immune responses, as well as regulations of immune cells.

Identifiants

pubmed: 34166709
pii: S0163-7827(21)00028-X
doi: 10.1016/j.plipres.2021.101112
pii:
doi:

Substances chimiques

Fatty Acids 0
Lysophospholipids 0
Phosphatidylserines 0
Phospholipases A1 EC 3.1.1.32

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101112

Subventions

Organisme : CIHR
ID : MOP-142210
Pays : Canada

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Yang Zhao (Y)

Centre de recherche du CHU de Québec-Université Laval, Centre ARThrite de l'Université Laval, Département de microbiologie-infectiologie et d'immunologie, Université Laval, Québec, G1V 4G2, Canada.

Stephan Hasse (S)

Centre de recherche du CHU de Québec-Université Laval, Centre ARThrite de l'Université Laval, Département de microbiologie-infectiologie et d'immunologie, Université Laval, Québec, G1V 4G2, Canada.

Sylvain G Bourgoin (SG)

Centre de recherche du CHU de Québec-Université Laval, Centre ARThrite de l'Université Laval, Département de microbiologie-infectiologie et d'immunologie, Université Laval, Québec, G1V 4G2, Canada. Electronic address: sylvain.bourgoin@crchudequebec.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH